Monoamine Oxidases and Their Selective Inhibition, Volume IV, documents the proceedings of the 3rd Congress of the Hungarian Pharmacological Society held in Budapest, 1979. The discovery of the selective monoamine oxidase (MAO) inhibitors, such as clorgyline and deprenyl, has given a new impetus to MAO research as well as to the clinical applicability of these compounds. This volume contains 21 papers by researchers and clinicians from eight different countries. It begins with papers on the pharmacological effects and the biochemical mode of actions of deprenyl as well as some other new selective inhibitors. This is followed by communications concerning the biochemical methods applied in the study of the nature of MAO in the mitochondrial membrane. Finally, the neurologists provide an account of their experience with the clinical application of deprenyl, and other inhibitors in Parkinsonian patients. They also discuss the essential role of the dopaminergic mechanism with respect to the disease.
Preface List of Contributors The Analysis of Amine Oxidases by the Use of Enzyme Inhibitors. Introductory Remarks Recent Clinical Studies in Monoamine Oxidase Inhibition Structure-Activity Relationship of Selective Inhibitors of MAO-B Selective Inhibitors of MAO-B with Different Pharmacological Profiles Is Methamphetamine a Therapeutically Important Metabolite of Deprenyl? Monoamine Oxidase Inhibitors (MAOIs) and Food Intake Deprenyl Inhibits Dopamine Uptake in the Rat Striatum In Vivo Gel Chromatography of Phenylalkylamines Human Platelet MAO-B - One Single Enzyme Form? Suicide Inhibitors of Monoamine Oxidase Purification and Properties of the Phenylhydrazine Adducts of Trimethylamine Dehydrogenase and of Monoamine Oxidase Selective Inhibition of MAO Induced by New Antidepressant Derivatives of Pyrazine-Indole Selective Inhibition of Monoamine Oxidase Type A by Some 4-Aminophenylisopropylamine Compounds Thiol Compounds and Monoamine Oxidase in Rat Liver and Brain Enzyme Stimulation and Inhibition as an Approach to Therapy for Parkinson's Disease Pharmacotherapy of Parkinsonism Clinical Experience in Extrapyramidal Disease with Selective MAOB Inhibitor, Deprenyl (-)Deprenyl Has a Band of Selectivity for Therapeutic Action The Action of L-Deprenyl in L-Dopa Treated Parkinsonian Patients, with Special Reference to the "on-off" Effect Long-Term L-Deprenyl Treatment of on-off Phenomena in Parkinson's Disease Late Kinetic Effects of L-Dopa and Combined Therapy in Parkinson's Disease Subject Index
- No. of pages:
- © Pergamon 1980
- 1st January 1980
- eBook ISBN: